Mixed claims in Health Technology Assessment: The case of Non-Invasive Prenatal Testing.

Health technology assessment Mixed claims Non-invasive prenatal testing Normativity The Netherlands Values

Journal

Social science & medicine (1982)
ISSN: 1873-5347
Titre abrégé: Soc Sci Med
Pays: England
ID NLM: 8303205

Informations de publication

Date de publication:
02 2021
Historique:
revised: 17 12 2020
accepted: 04 01 2021
pubmed: 20 1 2021
medline: 25 5 2021
entrez: 19 1 2021
Statut: ppublish

Résumé

Health Technology Assessment (HTA) uses explicit methods to determine the value of a health technology. This typically results in several claims regarding the effects that are expected to follow from the use of a health technology in a particular context. These claims seem to capture conclusions based solely on facts, but they often combine empirical information with normative presuppositions. Claims that have this character reflect (implicit) value judgments and have been labelled mixed claims. Not recognizing these normative components of such claims risks value inattention and value imposition, presenting results as self-evident and not in need of any moral justification. As proposed by Anna Alexandrova, to avoid these risks of value inattention and imposition we need rules to deal with mixed claims. According to her, when producing and evaluating mixed claims we need to unearth the invoked value presuppositions and check whether these presuppositions are invariant to disagreements. By applying these rules, the robustness of mixed claims can be checked: it can be evaluated whether their truth value is independent from the way in which their components, involving normative presuppositions, are conceptualized. This paper aims to illustrate the role of mixed claims in HTA, and expand upon the work by Alexandrova, by analyzing claims and recommendations presented in an HTA report on the introduction of Non-Invasive Prenatal Testing (NIPT) in The Netherlands. Our results show that the report contains mixed claims, and that a normative analysis of these claims can help to clarify the normativity of HTA and evaluate the robustness of claims on alleged effects of a health technology.

Identifiants

pubmed: 33465598
pii: S0277-9536(21)00021-6
doi: 10.1016/j.socscimed.2021.113689
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113689

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Bart Bloemen (B)

Department for Health Evidence, Radboud University Medical Centre, PO Box 9101, 6500HB, Nijmegen, the Netherlands. Electronic address: bart.bloemen1@radboudumc.nl.

Maarten Jansen (M)

Department for Health Evidence, Radboud University Medical Centre, PO Box 9101, 6500HB, Nijmegen, the Netherlands.

Wouter Rijke (W)

Department for Health Evidence, Radboud University Medical Centre, PO Box 9101, 6500HB, Nijmegen, the Netherlands.

Wija Oortwijn (W)

Department for Health Evidence, Radboud University Medical Centre, PO Box 9101, 6500HB, Nijmegen, the Netherlands.

Gert Jan van der Wilt (GJ)

Department for Health Evidence, Radboud University Medical Centre, PO Box 9101, 6500HB, Nijmegen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH